Glucotrack Inc. (NASDAQ: GCTK) announced the publication of a peer-reviewed study in the IEEE Sensors Journal examining the long-term stability of electrochemical glucose sensors used in its implantable continuous blood glucose monitoring system.

The study, titled "Year-Long Measurement of Glucose Oxidase Deactivation in Electrochemical Glucose Sensors," represents the first year-long measurement of glucose oxidase enzyme decay reported in scientific literature, according to the company's press release. The research examined sensor performance over a one-year period using devices constructed to reflect approximately two-year-old technology.

Glucotrack partnered with TTP, a United Kingdom-based scientific and engineering organization, for the study published on April 7, 2026. The research assessed sensor performance during the final year of its intended functional life to support the feasibility of long-life implantable continuous glucose monitors.

"This work provides externally reviewed scientific evidence relevant to the design of long-life implantable glucose sensors," said Dr. Paul Goode, President and Chief Executive Officer of Glucotrack. The company stated this publication forms part of its effort to build a peer-reviewed technical foundation for its continuous blood glucose monitoring technology development.

Glucotrack's continuous blood glucose monitoring system is designed as a long-term implantable device with a sensor longevity of three years, no on-body wearable component, and minimal calibration requirements. The company previously reported clinical results showing a mean absolute relative difference of 7.7% and a 99% data capture rate with no procedure- or device-related serious adverse events.

The company indicated it plans to submit an Investigational Device Exemption application with the FDA in the near term. Glucotrack's device remains investigational and is limited to investigational use under federal law.